# jRCT2051260010 (NCT06427941)

> A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06427941
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: BeOne Medicines
- Conditions: Metastatic Hepatocellular Carcinoma; Local Advanced Hepatocellular Carcinoma; Alpha-fetoprotein (AFP)-Producing Gastric Cancer; Extragonadal Yolk Sac Tumors; Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer
- Interventions: BGB-B2033; Tislelizumab; Bevacizumab
- Enrollment: 630
- Primary outcome: Part A and B: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
- Primary outcome: Part A and B: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of BGB-B2033
- Primary outcome: Part A and B: Recommended Phase 2 dose (RP2D) of BGB-B2033
- Primary outcome: Parts C, D, and E: Overall Response Rate (ORR) as assessed by the Independent Review Committee (IRC)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=jrct2051260010-nct06427941